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Background
The gut mucosal homing integrin receptor a4b7 present
on activated CD4+ T-cells interacts with the HIV-1 gp120
second variable loop (V2). Case control analysis of the
RV144 phase III vaccine trial showed that antibodies
induced by the vaccine bound to a MuLV-gp70 scaffolded
V1V2 loop of gp120 (V1V2-gp70) and correlated inversely
with infection. These, and other data, generate the hypoth-
esis that the vaccine-elicited antibodies may have been
involved in limiting HIV-1 acquisition. We have developed
a high-throughput assay to evaluate antibodies that block
a4b7 binding. We have named this the RAP assay.
Methods
Plates were coated with either MAdCAM-1, the natural
ligand of a4b7, or streptavidin followed by the addition of
biotinylated cyclic-V2 peptides (strain 92TH023 or MN).
Plasma and purified IgG antibodies from RV144 volun-
teers, conformational mAbs specific for V2 (697), for V2
and V3 (PG9, PG16), or for V2 linear epitopes (CH58 and
CH59, cloned from RV144 vaccinee B cells) were then
added to the peptide-coated plates followed by RPMI8866
cells, which constitutively express a4b7. Cell binding/inhi-
bition was assessed by AlamarBlue. Anti-a4b7-specific
mAb (ACT-1) served as a control. In separate experi-
ments, plasma, IgG, or mAbs were tested in a competition
assay using V1V2-gp70.
Results
ACT-1 inhibited the binding of both MAdCAM-1 and
cyclic-V2 peptides to a4b7 by 65-85%, while CH58 and
CH59 inhibited the a4b7-cyclic-V2 peptide binding by
37-45% in a dose-dependent manner. PG9, PG16, and
697 did not inhibit the binding of V2-peptides to the
cells. However, in the competition assay, 697 and PG9
mAbs inhibited V1V2-gp70 binding to a4b7. Some of
the RV144 plasma and IgG inhibited binding to
92TH023 or MN-V2-peptides.
Conclusion
We have developed a novel high-throughput reproduci-
ble assay for assessing a4b7-specific blocking antibodies.
The above results raise the hypothesis that anti-V2 loop
antibodies may play a role in regulation of gp120-a4b7
interaction.
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